33rd Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®
Past Events

Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 23.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTINUING EDUCATION CREDIT (Pharmacists, Nurses, Nurse Practitioners, and Physician Assistants):
You will receive a certificate of attendance for the CME-certified sessions (those designated for AMA/PRA Category 1 Credits™) which may be submitted to state licensing boards for determination of credit reciprocity (conversion to CEUs).

Acknowledgment of Commercial Support

This activity is supported by educational grants from Astellas, AstraZeneca, Boston Biomedical Pharma, Inc., Celgene Corporation, Clovis Oncology, Eisai Inc., Exelixis, Incyte Corporation, Ipsen Biopharmaceuticals, Inc., Lilly, Merck & Co., Inc., Merrimack Pharmaceuticals, Nektar Therapeutics, Novartis Pharmaceuticals Corporation, Novocure, Pharmacyclics, Inc. and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Puma Biotechnology, Taiho Oncology, Inc., and Takeda Oncology.

For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

The Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® is wholly owned and operated by PER Events, LLC, an affiliate of Physicians' Education Resource®.
33rd Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®

Chemotherapy Foundation Symposium brochure
Click here to download brochure
November 4 - 6, 2015
New York Marriott Marquis
1535 Broadway
New York, NY 10036


State-of-the-art cancer care continues to evolve due to advances in all aspects of patient care - including diagnosis, and personalized treatment and management. Through the incorporation of novel diagnostics, systemic therapies, molecular targeted therapies, immunotherapies, and other biotechnological strategies into treatment paradigms, patient outcomes continue to improve along the cancer continuum. The annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® (CFS), has brought together over 2,000 oncologists, hematologists, radiation oncologists, immunologists, oncology nurses, nurse practitioners, physician assistants, and case managers each year for 32 years, with the aim of educating these disciplines on state-of-the-art treatments across solid and hematologic malignancies and diverse clinical scenarios. At the 33rd Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® (CFS), our outstanding faculty of leading clinical innovators in virtually every tumor subspecialty will continue to provide expert insights on new developments in cancer therapeutics, and provide oncology professionals with the opportunity to learn about new compounds, novel approaches to diagnosis and treatment with currently available agents, ongoing clinical trials, and emerging developments that define current progress aimed at the goal of control and cure of cancer.

Target Audience

This educational program is directed toward oncologists and hematologists interested in the treatment of patients with cancer. Radiotherapists, immunologists, fellows, nurse practitioners, nurses, physician assistants, researchers, case managers, and other health care professionals interested in the treatment of cancer are also invited to attend. 

Program Co-Chairs

Edward Ambinder, MD
Clinical Professor
Medicine, Hematology and Medical Oncology
Clinical Professor, Oncological Sciences
Mount Sinai Hospital
New York, NY

Franco Muggia, MD
Professor, Department of Medicine
NYU Langone Medical Center
New York, NY

Steering Committee

Kimberly L. Blackwell, MD
Medical Oncologist
Duke Cancer Center
Durham, NC

C. Ola Landgren, MD, PhD
Hematologic Oncologist
Chief, Myeloma Service
Memorial Sloan Kettering Cancer Center
New York, NY

Jason J. Luke, MD
Medical Oncologist
Assistant Professor of Medicine
University of Chicago Medicine
Chicago, IL

John L. Marshall, MD
Chief, Division of Hematology/Oncology
Georgetown University Hospital
Associate Director, Clinical Research
Lombardi Comprehensive Cancer Center
Washington, DC

William K. Oh, MD
Chief, Division of Hematology and Medical Oncology
Professor of Medicine and Urology
Ezra M. Greenspan, MD Professor in Clinical Cancer Therapeutics
Icahn School of Medicine at Mount Sinai
Associate Director, Clinical Research
The Tisch Cancer Institute
New York, NY

Naiyer Rizvi, MD
Director, Thoracic Oncology
Director, Immunotherapeutics
Price Chair, Clinical Translational Research
Columbia University Medical Center
New York, NY


Agenda Highlights

Wednesday, November 4, 2015
Hematologic Malignancies
Chronic Lymphocytic Leukemia
Multiple Myeloma
Myeloproliferative Neoplasms
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Chronic Myeloid Leukemia
Immunotherapy & CAR T-Cell Therapy
Gastrointestinal Cancers
Colorectal Cancer
Gastric Cancers
Hepatocellular Carcinoma
Pancreatic Cancer
Soft Tissue Sarcoma
Thursday, November 5, 2015
Gynecologic Malignancies
Head and Neck Cancers
Oncology Informatics
The Future of Immuno-Oncology
Central Nervous System Tumors
Neuroendocrine Tumors
Chemotherapy-Induced Nausea and Vomiting
Breast Cancer
Friday, November 6, 2015
Value-Based Oncology
Lung Cancers
Cutaneous Malignancies
Genitourinary Malignancies
Diverse Topics

Click here to see the full agenda

Calendar of Events
Filter By